Biocept (BIOC) Reports Q3 Loss of $0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biocept Reports Third Quarter 2015 Financial Results
November 5, 2015 4:05 PM ESTSAN DIEGO, Nov. 5, 2015 /PRNewswire/ --Â Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of cancer, today reported financial results for the three and nine months ended September 30, 2015, and provided an update on business progress.Â
"During the third quarter we launched proprietary quantitative assays that target important mutations in colorectal cancer, melanoma and small cell lung cancer, building on what we believe to be the largest... More
Lung Cancer Study Demonstrates Extremely High Sensitivity of Biocept's Blood-Based Liquid Biopsy Platform in Detecting EGFR Mutation in Plasma with 93% Concordance with Tissue Biopsy
November 5, 2015 7:00 AM ESTData for the detection and monitoring of key predictive biomarkers for patients with newly diagnosed or progressing metastatic lung cancer on therapy to be presented at the Association for Molecular Pathology Annual Meeting
SAN DIEGO--(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company commercializing and developing biomarkers used in liquid biopsies to improve the detection and treatment of cancer, today announced that findings demonstrating the ability to reliably detect actionable genetic alterations used in the diagnosis, monitoring and treatment of patients with lung cancer using its... More
